Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region

Chih Hsing Wu, Yin Fan Chang, Chung Hwan Chen, E. Michael Lewiecki, Christian Wüster, Ian Reid, Keh Sung Tsai, Toshio Matsumoto, Leilani B. Mercado-Asis, Ding Cheng Chan, Jawl Shan Hwang, Ching Lung Cheung, Kenneth Saag, Joon Kiong Lee, Shih Te Tu, Weibo Xia, Wei Yu, Yoon Sok Chung, Peter Ebeling, Ambrish MithalSerge Livio Ferrari, Cyrus Cooper, Gau Tyan Lin, Rong Sen Yang

研究成果: Article

1 引文 (Scopus)

摘要

Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low adherence rates of medical treatment of osteoporosis, the experts reached consensus on the use of BTMs for both raising awareness and short-term monitoring of osteoporosis treatment in the AP region. The experts endorse the use of BTMs, especially serum C-terminal telopeptide of type 1 collagen (CTX) and serum procollagen type 1 N propeptide (P1NP), as short-term monitoring tools to help clinicians assess the responses to osteoporosis therapies and appropriately adjust treatment regimens earlier than BMD. Either the absolute values or the degree of change from baseline in BTMs can be used to monitor the potential efficacy of osteoporosis therapies. The use of BTMs can be incorporated in osteoporosis care programs, such as fracture liaison service (FLS), to improve patient adherence and treatment outcomes. Encouraging sufficient reimbursement from health care systems may facilitate widespread use of BTMs in clinical practice in the AP region.

原文English
期刊Journal of Clinical Densitometry
DOIs
出版狀態Published - 2019 一月 1

指紋

Bone Remodeling
Osteoporosis
Consensus
Bone Density
Therapeutics
Photon Absorptiometry
Hip Fractures
Collagen Type I
Biomarkers
Patient Compliance
Delivery of Health Care
Costs and Cost Analysis
Health

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Radiology Nuclear Medicine and imaging

引用此文

Wu, Chih Hsing ; Chang, Yin Fan ; Chen, Chung Hwan ; Lewiecki, E. Michael ; Wüster, Christian ; Reid, Ian ; Tsai, Keh Sung ; Matsumoto, Toshio ; Mercado-Asis, Leilani B. ; Chan, Ding Cheng ; Hwang, Jawl Shan ; Cheung, Ching Lung ; Saag, Kenneth ; Lee, Joon Kiong ; Tu, Shih Te ; Xia, Weibo ; Yu, Wei ; Chung, Yoon Sok ; Ebeling, Peter ; Mithal, Ambrish ; Ferrari, Serge Livio ; Cooper, Cyrus ; Lin, Gau Tyan ; Yang, Rong Sen. / Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. 於: Journal of Clinical Densitometry. 2019.
@article{4aff9acb04a94a17b3c8962007dbb108,
title = "Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region",
abstract = "Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50{\%} of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low adherence rates of medical treatment of osteoporosis, the experts reached consensus on the use of BTMs for both raising awareness and short-term monitoring of osteoporosis treatment in the AP region. The experts endorse the use of BTMs, especially serum C-terminal telopeptide of type 1 collagen (CTX) and serum procollagen type 1 N propeptide (P1NP), as short-term monitoring tools to help clinicians assess the responses to osteoporosis therapies and appropriately adjust treatment regimens earlier than BMD. Either the absolute values or the degree of change from baseline in BTMs can be used to monitor the potential efficacy of osteoporosis therapies. The use of BTMs can be incorporated in osteoporosis care programs, such as fracture liaison service (FLS), to improve patient adherence and treatment outcomes. Encouraging sufficient reimbursement from health care systems may facilitate widespread use of BTMs in clinical practice in the AP region.",
author = "Wu, {Chih Hsing} and Chang, {Yin Fan} and Chen, {Chung Hwan} and Lewiecki, {E. Michael} and Christian W{\"u}ster and Ian Reid and Tsai, {Keh Sung} and Toshio Matsumoto and Mercado-Asis, {Leilani B.} and Chan, {Ding Cheng} and Hwang, {Jawl Shan} and Cheung, {Ching Lung} and Kenneth Saag and Lee, {Joon Kiong} and Tu, {Shih Te} and Weibo Xia and Wei Yu and Chung, {Yoon Sok} and Peter Ebeling and Ambrish Mithal and Ferrari, {Serge Livio} and Cyrus Cooper and Lin, {Gau Tyan} and Yang, {Rong Sen}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jocd.2019.03.004",
language = "English",
journal = "Journal of Clinical Densitometry",
issn = "1094-6950",
publisher = "Elsevier Inc.",

}

Wu, CH, Chang, YF, Chen, CH, Lewiecki, EM, Wüster, C, Reid, I, Tsai, KS, Matsumoto, T, Mercado-Asis, LB, Chan, DC, Hwang, JS, Cheung, CL, Saag, K, Lee, JK, Tu, ST, Xia, W, Yu, W, Chung, YS, Ebeling, P, Mithal, A, Ferrari, SL, Cooper, C, Lin, GT & Yang, RS 2019, 'Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region', Journal of Clinical Densitometry. https://doi.org/10.1016/j.jocd.2019.03.004

Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. / Wu, Chih Hsing; Chang, Yin Fan; Chen, Chung Hwan; Lewiecki, E. Michael; Wüster, Christian; Reid, Ian; Tsai, Keh Sung; Matsumoto, Toshio; Mercado-Asis, Leilani B.; Chan, Ding Cheng; Hwang, Jawl Shan; Cheung, Ching Lung; Saag, Kenneth; Lee, Joon Kiong; Tu, Shih Te; Xia, Weibo; Yu, Wei; Chung, Yoon Sok; Ebeling, Peter; Mithal, Ambrish; Ferrari, Serge Livio; Cooper, Cyrus; Lin, Gau Tyan; Yang, Rong Sen.

於: Journal of Clinical Densitometry, 01.01.2019.

研究成果: Article

TY - JOUR

T1 - Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region

AU - Wu, Chih Hsing

AU - Chang, Yin Fan

AU - Chen, Chung Hwan

AU - Lewiecki, E. Michael

AU - Wüster, Christian

AU - Reid, Ian

AU - Tsai, Keh Sung

AU - Matsumoto, Toshio

AU - Mercado-Asis, Leilani B.

AU - Chan, Ding Cheng

AU - Hwang, Jawl Shan

AU - Cheung, Ching Lung

AU - Saag, Kenneth

AU - Lee, Joon Kiong

AU - Tu, Shih Te

AU - Xia, Weibo

AU - Yu, Wei

AU - Chung, Yoon Sok

AU - Ebeling, Peter

AU - Mithal, Ambrish

AU - Ferrari, Serge Livio

AU - Cooper, Cyrus

AU - Lin, Gau Tyan

AU - Yang, Rong Sen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low adherence rates of medical treatment of osteoporosis, the experts reached consensus on the use of BTMs for both raising awareness and short-term monitoring of osteoporosis treatment in the AP region. The experts endorse the use of BTMs, especially serum C-terminal telopeptide of type 1 collagen (CTX) and serum procollagen type 1 N propeptide (P1NP), as short-term monitoring tools to help clinicians assess the responses to osteoporosis therapies and appropriately adjust treatment regimens earlier than BMD. Either the absolute values or the degree of change from baseline in BTMs can be used to monitor the potential efficacy of osteoporosis therapies. The use of BTMs can be incorporated in osteoporosis care programs, such as fracture liaison service (FLS), to improve patient adherence and treatment outcomes. Encouraging sufficient reimbursement from health care systems may facilitate widespread use of BTMs in clinical practice in the AP region.

AB - Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low adherence rates of medical treatment of osteoporosis, the experts reached consensus on the use of BTMs for both raising awareness and short-term monitoring of osteoporosis treatment in the AP region. The experts endorse the use of BTMs, especially serum C-terminal telopeptide of type 1 collagen (CTX) and serum procollagen type 1 N propeptide (P1NP), as short-term monitoring tools to help clinicians assess the responses to osteoporosis therapies and appropriately adjust treatment regimens earlier than BMD. Either the absolute values or the degree of change from baseline in BTMs can be used to monitor the potential efficacy of osteoporosis therapies. The use of BTMs can be incorporated in osteoporosis care programs, such as fracture liaison service (FLS), to improve patient adherence and treatment outcomes. Encouraging sufficient reimbursement from health care systems may facilitate widespread use of BTMs in clinical practice in the AP region.

UR - http://www.scopus.com/inward/record.url?scp=85064464601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064464601&partnerID=8YFLogxK

U2 - 10.1016/j.jocd.2019.03.004

DO - 10.1016/j.jocd.2019.03.004

M3 - Article

AN - SCOPUS:85064464601

JO - Journal of Clinical Densitometry

JF - Journal of Clinical Densitometry

SN - 1094-6950

ER -